Aclaris Therapeutics publishes ATI-052 Phase 1b results in atopic dermatitis and asthma
ACRS•Aclaris Therapeutics published Phase 1b results for ATI-052, supporting advancement into a staged Phase 2b program. At week eight, eczema severity scores fell 58% from baseline versus 13% with placebo; in asthma, a single dose reduced fractional exhaled nitric oxide 59% by day 15 versus 15% with placebo, while lung function improved by a placebo-adjusted 200 milliliters.
1. Phase 1b results
Aclaris Therapeutics published Phase 1b results for ATI-052 in atopic dermatitis and asthma, supporting advancement into a staged Phase 2b program. At week eight, eczema severity scores fell 58% from baseline versus 13% with placebo. In asthma, a single dose reduced fractional exhaled nitric oxide 59% by day 15 versus 15% with placebo, and lung function improved by a placebo-adjusted 200 milliliters in the overall asthma population. Neither trial recorded serious treatment-emergent adverse events or discontinuations due to treatment-emergent adverse events.
